Schrödinger

New York, New York, USA All United States companies → — Founded 1990

Biotech / Drug Discovery

Hematology Infectious Disease Oncology

Drug Discovery & Research Pharmacology & Dosing AI

Public — $394.6M

Website Claim this company

Products

Schrödinger (various platforms)

Schrödinger

Drug Discovery & Research

Schrödinger provides physics-based simulation and machine learning platforms for drug discovery and materials science, widely used in pharmaceutical research for predicting molecular interactions.

Contact for pricing

See all 1 product →

About Schrödinger

Schrödinger is a scientific software and biotechnology company that has pioneered a physics-based computational platform for accelerated molecular discovery and design. For physicians, this means a transformative approach to drug development, enabling the rapid and accurate identification of high-quality, novel molecules for therapeutic applications. The company’s platform integrates advanced algorithms and high-performance computing to simulate molecular interactions with high accuracy, allowing researchers to predict properties, optimize compounds, and design new therapeutics more efficiently than traditional methods.

Schrödinger’s technology is utilized across various stages of the drug discovery pipeline, from lead identification to preclinical development. Their software tools include molecular dynamics simulations, free energy calculations, quantum mechanics calculations, and virtual screening tools. Beyond licensing its computational platform to biopharmaceutical companies, academic institutions, and government laboratories, Schrödinger also leverages its software internally to advance a portfolio of collaborative and proprietary drug discovery programs aimed at addressing unmet medical needs. These internal programs primarily focus on oncology, immunology, and neurology, with assets spanning discovery, preclinical, and clinical stages.

Focus Areas

drug discovery materials science computational chemistry molecular modeling biologics discovery small molecule discovery enterprise informatics

Business Intelligence

Key Investors	Bill & Melinda Gates Foundation, WuXi AppTec, Baron Capital Management, Deerfield, GV, Qiming Venture Partners, Invus, Pavilion Capital Partners, Michael Antonov (Tubus Management), Laurion Capital Management, Formic Ventures, Sixty Degree Capital
Partnerships	Eli Lilly, Novartis, Ajax Therapeutics, Otsuka Pharmaceutical Co., Ltd.
Acquisitions	Xtal BioStructures (2022)
Technology	physics-based computational platform, machine learning, cloud-native (Google Cloud), molecular dynamics simulations, free energy calculations, quantum mechanics calculations, virtual screening tools, LiveDesign (enterprise informatics platform), Maestro (molecular modeling interface), Glide (molecular docking), FEP+, BioLuminate (biologics tools), MS Maestro, Desmond (molecular dynamics), Jaguar (quantum chemistry), MS LiveDesign
FDA Clearances	0 (currently has investigational new drug (IND) applications cleared and Fast Track designations for pipeline assets) cleared products (estimated)

What Physicians Need to Know

Drug Discovery (Small Molecule)

Schru00f6dinger leverages its physics-based computational platform, enhanced with AI and machine learning, to accelerate small molecule drug discovery. They can explore vast chemical spaces, triage billions of compounds, and rapidly identify promising drug candidates. For instance, their platform enabled the discovery of SGR-1505, a MALT1 inhibitor for B-cell malignancies, in approximately 10 months, a process that traditionally takes 3-6 years and thousands of synthesized molecules.

Biologics & Mixed Modalities

The platform supports the discovery and engineering of biologics, including antibody design, peptide discovery, and enzyme engineering. This allows for the development of next-generation biologics by simulating and optimizing molecular interactions at scale.

Materials Science

Schru00f6dinger's digital chemistry platform for molecular simulation of materials is used across various industries like organic electronics, catalysis, and energy storage. It enables the prediction of key properties for better materials, including simulating polymers, designing new polymers, and predicting optoelectronic properties for organic electronics.

Key Differentiators

Their core differentiation lies in a physics-based computational platform combined with AI and machine learning. This approach allows for highly accurate *in silico* predictions of molecular behavior and interactions, significantly reducing the time and cost associated with traditional R&D. They also emphasize a cloud-native, collaborative molecular design platform (LiveDesign) and scalable cloud computing (Virtual Cluster).

Technology Stack

The technology stack is centered around their Maestro platform, which utilizes physics-based computational methods and advanced machine learning algorithms. Key components include the Free Energy Perturbation (FEP+) model for protein-ligand systems, optimized with machine learning and automation. They offer cloud-native solutions, including a Virtual Cluster that provides access to Schru00f6dinger software in a standardized, secure, and scalable cloud computing environment, partnered with Google Cloud and NVIDIA.

Physician Tip

For physicians, Schru00f6dinger's work translates to a faster and more efficient drug discovery pipeline, potentially leading to novel and more effective therapeutic options reaching patients sooner. Their focus on physics-based computational approaches aims to reduce the risk in drug development by selecting high-value targets and solving complex design challenges. For example, their MALT1 inhibitor, SGR-1505, is already in Phase 1 clinical trials for B-cell malignancies, demonstrating the real-world impact of their platform. This approach could mean more targeted and potentially 'best-in-class' compounds for various diseases.

Schru00f6dinger's platform is designed for integration, offering solutions that can integrate with corporate data sources and allow for the snap-in of web-based or in-house developed technologies via a model-agnostic API. They also offer flexible data management and cloud computing solutions, including deploying Maestro to the cloud with auto-scaling capabilities and integration with industry-standard queuing systems. Recent strategic agreements include the integration of Lilly's TuneLab platform into Schru00f6dinger's LiveDesign enterprise informatics solution.

At a glance

Founded 1990

HQ New York, New York, USA · United States

Team size 850-1015

CEO Ramy Farid, Ph.D.

Funding Public — $394.6M

FDA clearances 0 (currently has investigational new drug (IND) applications cleared and Fast Track designations for pipeline assets) (estimated)

Products 1

Visit site

Products by Schrödinger

1 product in the directory

Schrödinger (various platforms)

Schrödinger

Drug Discovery & Research

Schrödinger provides physics-based simulation and machine learning platforms for drug discovery and materials science, widely used in pharmaceutical research for predicting molecular interactions.

Contact for pricing

What the Web Says

Schru00f6dinger is a company that provides a physics-based computational platform for drug discovery and materials science, utilizing AI and machine learning to accelerate research and reduce costs. The company's software is widely used by pharmaceutical and biotechnology companies, including all of the top 20 pharmaceutical companies. While their software products generally receive positive feedback for their capabilities and user-friendliness, there are mixed opinions regarding the company as an employer, particularly concerning management, career advancement, and the hiring process.

Overall: Mixed

Strengths

Many options for research and drug design.
Clean and interactive user interface.
Reproducible and reliable results.
No coding knowledge needed for many functions.
Excellent customer service and quick responses.
Accelerates drug discovery and reduces costs.

Limitations

Software can be costly compared to open-source alternatives.
Limited flexibility in follow-up instructions for power users.
Concerns about competence of middle management.
Promotion decisions may not always reward those who contribute the most.
Long and drawn-out interview process.
Some employees feel undervalued and easily replaceable.

Based on reviews from: G2, Capterra, Reddit, Indeed.com, MarketBeat, Pharma Now, Slashdot

Last updated: 2026-07-03

Videos

News, demos, and interviews about Schrödinger.

Loading videos...

Videos load interactively. If none appear, search YouTube for Schrödinger →

View all on YouTube

Press & Coverage

Schru00f6dinger, Inc. (Nasdaq)

Schru00f6dinger Announces FDA Clearance of Investigational New Drug Application for SGR-1505, a MALT1 Inhibitor

Schru00f6dinger announced that the FDA cleared its IND application for SGR-1505, a MALT1 inhibitor, for a Phase 1 clinical trial in patients with relapsed or refractory B-cell lymphoma.

2022-06

Business Wire

Schru00f6dinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenstru00f6m Macroglobulinemia

Schru00f6dinger announced that SGR-1505, its clinical stage MALT1 inhibitor, received Fast Track designation from the FDA for treating adult patients with Waldenstru00f6m macroglobulinemia who have failed at least two lines of therapy.

2025-06

New York State Governor's Office

Governor Hochul Announces $7.6 Million Expansion of Schru00f6dinger Headquarters in New York City

Governor Kathy Hochul announced Schru00f6dinger's $7.6 million investment to expand its headquarters in New York City, creating at least 80 new jobs and retaining 310 full-time jobs to support drug discovery and materials science.

2023-03

Schru00f6dinger, Inc. (Nasdaq)

Schru00f6dinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities

Schru00f6dinger provided an update on its 2024 achievements and 2025 strategic priorities, including the launch of an initiative to expand its computational platform for toxicology risk prediction and a research collaboration with Novartis.

2025-01

Schru00f6dinger, Inc. (Nasdaq)

Schru00f6dinger Announces Acquisition of XTAL BioStructures, Inc.

Schru00f6dinger announced the acquisition of XTAL BioStructures, a company providing structural biology services, to enhance its ability to produce high-quality target structures for drug discovery programs.

2022-01

Schru00f6dinger, Inc. (Nasdaq)

Schru00f6dinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

Schru00f6dinger highlighted progress in its collaborative portfolio and co-founded companies, including expanded research collaborations with Ajax Therapeutics, Lilly, and Otsuka Pharmaceutical Co., Ltd.

2026-01

GuruFocus

Rubric Capital Management LP's Strategic Acquisition of Schrodinger Inc Shares

Rubric Capital Management LP increased its holdings in Schru00f6dinger Inc., reflecting confidence in the company's growth potential in the healthcare sector.

2025-02

Frequently Asked Questions

What specific drug discovery modalities does Schru00f6dinger's platform support that are relevant to my practice or institution?

Schru00f6dinger's platform offers comprehensive support for a wide range of drug discovery modalities, including small molecule and biologics discovery. This encompasses advanced capabilities in antibody design, peptide discovery, enzyme engineering, and the development of bifunctional degraders. Additionally, it provides tools for T-cell receptor (TCR) modeling, enabling a broad spectrum of therapeutic research and development.

Beyond drug discovery, how does Schru00f6dinger's technology apply to materials science, and could this be relevant for healthcare innovations or operational efficiencies?

Schru00f6dinger's materials science solutions extend to areas like organic electronics, catalysis, and energy storage. While not directly clinical, these applications could indirectly impact healthcare through the development of advanced medical devices, more efficient energy solutions for healthcare facilities, or novel materials for drug delivery systems.

What are Schru00f6dinger's main products or platforms that a healthcare organization would utilize for research and development?

Schru00f6dinger's flagship product is its physics-based computational platform, which integrates a suite of software solutions for drug discovery and materials science. This platform includes tools for molecular modeling, simulations, and data analysis, designed to accelerate the design and optimization of novel compounds and materials.

How does Schru00f6dinger ensure compliance and data security for sensitive research data, especially in a healthcare context?

Schru00f6dinger is committed to maintaining high standards of data security and compliance. While specific certifications would need to be verified, their platform is designed with robust security features to protect intellectual property and sensitive research data, which is crucial for healthcare-related R&D.

What is the typical pricing model for Schru00f6dinger's platform, and are there options for academic institutions or smaller research groups?

Schru00f6dinger typically offers various licensing models for its software, which can include subscriptions based on usage or specific modules. They often have tailored programs and pricing structures for academic institutions and smaller research groups to foster broader adoption and collaboration.

What kind of technical support and scientific expertise does Schru00f6dinger provide to its users?

Schru00f6dinger provides extensive technical support and scientific expertise to its users, including dedicated support teams, training programs, and access to their in-house scientists. This ensures users can effectively leverage the platform's advanced capabilities for their specific research needs.

Does Schru00f6dinger engage in partnerships with pharmaceutical companies or academic institutions, and how might such partnerships benefit my organization?

Yes, Schru00f6dinger actively engages in partnerships with leading pharmaceutical companies, biotechnology firms, and academic institutions globally. These collaborations often involve co-development projects, licensing agreements, and research alliances, which can provide partner organizations with access to cutting-edge technology, shared expertise, and accelerated research outcomes.

What is Schru00f6dinger's company stability and long-term vision, particularly concerning ongoing platform development and support?

Schru00f6dinger is a publicly traded company with a strong financial standing and a clear long-term vision focused on advancing computational chemistry and materials science. They consistently invest in research and development to enhance their platform, ensuring ongoing innovation and sustained support for their users.

Related Companies

Suggest an Edit →